About us
- >
- About us >
- Information >
- Announcement
2023-06-26
ENERGI-F703 diabetic foot ulcer topical gel has received approval from the Taiwan Food and Drug Administration (TFDA) to initiate Phase III clinical t
On June 26, 2023, We have received notification from the Contract Research Organization (CRO) that our investigational new drug, ENERGI-F703 topical gel for diabetic foot ulcers, has been granted approval by the Taiwan Food and Drug Administration (TFDA) to proceed with Phase III clinical trials in human subjects. This significant development allows us to advance in the clinical testing process to further evaluate the efficacy and safety of ENERGI-F703 for the treatment of diabetic foot ulcers.